Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.56 |
| ▸ | MAOB | P27338 | 4/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30341899 | 1.00 | MAOA (0.56) | MAOAMAOBBCHEADRA2BADRA2C | |
| SCHEMBL3932599 | 1.00 | MAOA (0.56) | MAOAMAOBBCHEADRA2BADRA2C | |
| SCHEMBL2467861 | 1.00 | MAOA (0.56) | MAOAMAOBBCHEADRA2BADRA2C | |
| SCHEMBL11145013 | 0.98 | MAOA (0.55) | MAOAMAOBBCHEADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL5969990 | 0.98 | MAOA (0.55) | MAOAMAOBBCHEADRA2BADRA2C | |
| SCHEMBL11145021 | 0.98 | MAOA (0.55) | MAOAMAOBBCHEADRA2BADRA2C | |
| SCHEMBL5901234 | 0.91 | HTT (0.61) | TAS1R3TAS1R1TAS1R2HTTALDH1A1 | |
| SCHEMBL5963105 | 0.87 | MAOA (0.45) | MAOAMAOBBCHEADRA2BADRA2C | |
| SCHEMBL7144288 | 0.86 | SCN3A (0.56) | MAOAMAOBBCHEADRA2BADRA2C | |
| SCHEMBL7144293 | 0.86 | SCN3A (0.56) | MAOAMAOBBCHEADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697246-B1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | GENESIS TECH LIMITED (BB) | 2018-03-07 | — | — | EP | claimed |
| CN-107445852-A | Preparation method of D-indanyl glycine | 浙江工业大学 | 2017-12-08 | — | — | CN | claimed |
| EP-2288615-B1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-06-21 | — | — | EP | claimed |
| US-9562069-B2 | Selective caspase inhibitors and uses thereof | NEW WORLD LABORATORIES INC. (CA) | 2017-02-07 | — | — | US | claimed |
| CN-102105485-B | Selectivity caspase inhibitors and uses thereof | NEW WORLD LABORATORIES INC. (CA) | 2016-01-13 | — | — | CN | claimed |
| US-9090658-B2 | Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2015-07-28 | — | — | US | claimed |
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2015-01-08 | — | — | US | claimed |
| WO-2014177406-A1 | COMPOSITION COMPRISING AT LEAST THREE ACTIVE AGENTS FOR COLOURING AND/OR PIGMENTING KERATIN MATERIALS | L'OREAL (FR) | 2014-11-06 | — | — | WO | claimed |
| US-8791235-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2014-07-29 | — | — | US | claimed |
| EP-2697246-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | Novagenesis Foundation (CH) | 2014-02-19 | — | — | EP | claimed |
| EP-0738149-A4 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 1999-10-27 | — | — | EP | claimed |
| US-5880159-A | TREATING ACUTE NEUROLOGICAL TRAUMATIC DISORDER OR NEUROTRAUMA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-09 | — | — | US | claimed |
| US-5877221-A | TREATING DEMENTIA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-02 | — | — | US | claimed |
| US-5811241-A | ATTACHING N-PROTECTED ALPHA-AMINO ACID TO POLYMERIC SUPPORT; DEPROTECTING; REDUCTIVE ALKYLATION; BROMOACETYLATION; REACTING WITH PRIMARY AMINE; CYCLIZATION; CLEAVAGE; FOR SYNTHESIZING COMBINATORIAL LIBRARIES | CORTECH, INC. (US) | 1998-09-22 | — | — | US | claimed |
| EP-0813544-A4 | — | — | 1998-01-07 | — | — | EP | claimed |
| EP-0813544-A1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH, INC. (US) | 1997-12-29 | — | — | EP | claimed |
| WO-1997010222-A1 | METHOD FOR PREPARING PIPERAZINES | CORTECH, INC. (US) | 1997-03-20 | — | — | WO | claimed |
| EP-0738149-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-10-23 | — | — | EP | claimed |
| WO-1995024422-A1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH, INC. (US) | 1995-09-14 | — | — | WO | claimed |
| WO-1995018617-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-07-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP3, CASP1, HTRA2 | MAOA 178/4885MAOB 361/4885BCHE 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.